in-vitro-in-vivo correlation (IVIVC)

Running a clinical study every time you tweak a formulation is slow and costly. IVIVC is the dream shortcut: a mathematical relationship that lets a bench-top dissolution test predict how the drug will be absorbed in people. If you can trust that 'what dissolves in the beaker' maps reliably onto 'what appears in the blood', the dissolution test becomes a surrogate for human studies.

Regulators recognize several levels. A Level A correlation — the most useful — is a point-to-point relationship between the in-vitro dissolution curve and the in-vivo absorption profile (often obtained by deconvolution), ideally one-to-one across the whole time course. Level B uses statistical moments (mean dissolution time versus mean residence time), Level C links a single dissolution point to a single pharmacokinetic parameter, and a multiple-Level-C correlation links several such points. Level A is the goal because it captures the full curve.

A validated IVIVC is most achievable for extended-release products, where dissolution is the rate-limiting step and the in-vitro method can be tuned to mirror gut conditions. Its payoff is regulatory: it can justify a biowaiver for certain post-approval changes (manufacturing site, equipment, modest formulation tweaks) and guide rational formulation design. The honest limit is that for rapidly absorbed immediate-release drugs, where dissolution is not rate-limiting, a meaningful correlation is often impossible to establish.